Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
A model for ovarian tumor progression is proposed in which the initial methylation of FANCF is followed by FancF demethylation and ultimately results in cisplatin resistance. Expand
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs. Expand
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
The data suggest that the malignant phenotype of metastatic ovarian cancer cells can be altered by miR21 delivered by exosomes derived from neighbouring stromal cells in the omental tumour microenvironment, and that inhibiting the transfer of stronal-derived miR 21 is an alternative modality in the treatment of metastatics and recurrent ovarian cancer. Expand
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
The expression profiles of LMP, low-grade, and high- grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low- grade cancers. Expand
TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.
A TGF-β-inducible gene signature specific to CAFs in advanced high-grade serous ovarian tumors is identified, and it is shown how T GF-β stimulates ovarian cancer cell motility and invasion by upregulating the CAF-specific gene VCAN. Expand
Dicer, Drosha, and outcomes in patients with ovarian cancer.
- W. Merritt, Yvonne G. Lin, +19 authors A. Sood
- The New England journal of medicine
- 18 December 2008
Levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer, and functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. Expand
Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells.
Comparisons of cell growth responses to gonadotropins and sex steroids in primary cultures of human OSE cells with those observed in immortalized, nontumorigenic HOSE cells and in OCa cell lines support the hypothesis that reproductive states associated with rising levels of gonadotropic hormone, estrogen, and/or androgen promote cell proliferation in the normal OSE, which favors neoplastic transformation. Expand
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
- S. Mok, J. Chao, +5 authors D. Cramer
- Biology, Medicine
- Journal of the National Cancer Institute
- 3 October 2001
Prostasin is overexpressed in epithelial ovarian cancer and should be investigated further as a screening or tumor marker, alone and in combination with CA 125. Expand
Osteopontin as a potential diagnostic biomarker for ovarian cancer.
The findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile. Expand
Potential markers that complement expression of CA125 in epithelial ovarian cancer.
At the level of tissue expression, each of 10 potential serum markers could be detected in 29-100% of ovarian cancers that had low or absent expression of CA125. Expand